HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Population
Patients with HER2+ breast cancer
Authors
Discussion
Loading...
Member takes
Implication
May inform refined monitoring in HER2+ breast cancer; leaves open prospective validation before clinical adoption.
Structured PICO
P
Population
Patients with HER2+ breast cancer
I
Intervention
Cardiotoxicity management (including new imaging modalities, biomarkers, interventional therapies)
This review highlights emerging techniques, including imaging and biomarkers, for managing cardiotoxicity in patients undergoing HER2+ breast cancer treatment.
Cite This Study
Jérusalem et al. (2019) studied this question.